By Senator Rodriguez

40-01424-25 2025648

A bill to be entitled

An act relating to the Diabetes Prevention and Obesity Treatment Act; creating s. 385.2035, F.S.; providing a short title; defining terms; beginning on a specified date, requiring the Agency for Health Care Administration to provide Medicaid coverage for diabetes prevention programs if the Medicaid recipient meets specified criteria; requiring the agency to provide Medicaid coverage for certain treatments for obesity; providing that covered services may be offered in various settings; providing construction; requiring the agency to adopt rules and provide written notification of certain information to Medicaid recipients; authorizing the agency to seek federal approval through a state plan amendment or Medicaid waiver if necessary to implement specified provisions; providing an effective date.

1819

1

2

3

4

5

6

7

8

9

10

11

1213

1415

1617

Be It Enacted by the Legislature of the State of Florida:

2021

Section 1. Section 385.2035, Florida Statutes, is created to read:

2223

385.2035 Diabetes prevention and obesity treatment.-

24

(1) SHORT TITLE.—This section may be cited as the "Diabetes Prevention and Obesity Treatment Act."

2526

(2) DEFINITIONS.—As used in this section, the term:

27

(a) "Agency" means the Agency for Health Care Administration.

2829

(b) "Diabetes prevention program" means structured

40-01424-25 2025648

behavioral health change sessions that are furnished to an eligible individual by a diabetes prevention program provider for the purpose of preventing or delaying the onset of type 2 diabetes and that follow a curriculum approved by the United States Centers for Disease Control and Prevention.

- (c) "Diabetes prevention program provider" means an entity that is recognized under the United States Centers for Disease Control and Prevention Diabetes Prevention Recognition Program to offer a diabetes prevention program through an approved delivery method, including in person, online, and distance learning, or a combination thereof, and other synchronous and asynchronous modalities.
- (d) "FDA-approved obesity medication" means any medication approved by the United States Food and Drug Administration with an indication for chronic weight management in patients with an obesity diagnosis.
- (e) "Intensive health behavioral and lifestyle treatment" means an evidence-based, intensive, multicomponent behavioral or lifestyle modification intervention that supports healthy weight management and is delivered in person or through telehealth as defined in s. 456.47.
- (f) "Metabolic and bariatric surgery" means any surgical intervention included in the most current American Society for Metabolic and Bariatric Surgery (ASMBS)/International Federation for the Surgery of Obesity and Metabolic Disorders Guidelines on Indications for Metabolic and Bariatric Surgery.
- (3) MEDICAID COVERAGE FOR DIABETES PREVENTION PROGRAMS.—
 Beginning January 1, 2026, the agency shall reimburse a diabetes prevention program provider for a Medicaid recipient's

40-01424-25 2025648

participation in the program if the recipient:

- (a) Meets the diabetes prevention program's eligibility requirements; and
- (b) Has not previously participated in the program while enrolled in the Medicaid program.
- (4) MEDICAID COVERAGE FOR MANAGEMENT AND TREATMENT OF OBESITY REQUIRED.—
- (a) The agency shall pay for the treatment of Medicaid recipients for the chronic disease of obesity, including, but not limited to, all of the following:
 - 1. Intensive health behavioral and lifestyle treatment.
 - 2. Metabolic and bariatric surgery.
 - 3. FDA-approved obesity medication.
- (b) The coverage criteria for an FDA-approved obesity medication may not be more restrictive than the FDA-approved indications for such medication.
- (c) Intensive health behavioral and lifestyle treatment may include interventions certified by or recognized by the United States Centers for Disease Control and Prevention or recommended by current clinical standards of care. The services may be provided in office settings, virtually, or in community-based settings to support patient access and needs.
- (d) This subsection does not prohibit the agency from applying its standard methodologies to determine the medical necessity or appropriateness of a course of treatment authorized under this section, provided that such determinations are made in the same manner as those made for the treatment of any other illness, condition, or disorder covered by the state Medicaid program.

88

89

90

91

92

93

94

95

40-01424-25 2025648___

(5) RULES.—The agency shall adopt rules to implement this section and shall notify Medicaid recipients in writing about the availability of treatment for the chronic disease of obesity and diabetes prevention programs under this section.

- (6) FEDERAL APPROVAL.—The agency may seek federal approval through a state plan amendment or a Medicaid waiver as needed to implement this section.
 - Section 2. This act shall take effect July 1, 2025.